YD Bio Limited has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery.
The MOU is non-binding, and there can be no assurance that YD Bio and EG BioMed will enter into definitive agreements, obtain required approvals, or consummate the merger on the terms contemplated or on any particular timeline. Any potential integration benefits, including revenue growth, platform expansion, or cost synergies, remain subject to numerous assumptions and risks and may not be realized. The transaction is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.
Strategic Rationale and Vision for the Future: From Single Technologies to a Platform-Based Biotech Ecosystem
As precision medicine and AI-driven drug development continue to reshape the biotechnology industry, we believe competitive advantage is increasingly defined by the ability to integrate high-quality biological data, advanced analytics, and clinical execution. If completed, the proposed merger with EG BioMed could accelerate YD Bio’s anticipated transition from a technology-focused company into a platform-based biotech organization anchored in clinically validated molecular data. However, any expected benefits remain subject to successful execution, data generation, regulatory pathways, and market adoption, none of which can be assured.
EG BioMed brings to the combined organization a robust DNA methylation diagnostics platform, AI-based biomarker algorithms, and certified clinical laboratory infrastructure, providing YD Bio with a critical upstream engine for diagnostics commercialization and therapeutic innovation.
By unifying diagnostics, therapeutics, real-world clinical data, and AI intelligence, YD Bio aims to reduce development risk, accelerate time-to-market, and build a scalable oncology innovation ecosystem addressing cancer from early detection through treatment monitoring and recurrence prevention, subject to successful execution and regulatory and market outcomes.
Synergies: Leveraging DNA Methylation Data for AI-Driven Drug Discovery
EG BioMed’s core technology is based on DNA methylation profiling, a powerful epigenetic approach that captures cancer-associated molecular changes with high sensitivity. The platform has demonstrated strong clinical performance in early cancer detection, including pancreatic cancer—one of the most lethal malignancies with significant unmet medical needs.
Beyond diagnostics, the merger enables YD Bio to transform DNA methylation datasets into strategic assets for AI-powered drug development. These clinically validated epigenetic datasets will be used to support AI-based target discovery, patient stratification, and recurrence-risk prediction. By applying advanced AI models to methylation-driven disease mechanisms, YD Bio aims to develop novel therapeutic approaches with the potential to reduce cancer recurrence and improve long-term patient outcomes.
“Prior to this announcement, EG BioMed’s cancer detection platform was approved for clinical adoption at three affiliated medical centers of Taipei Medical University. It is now being integrated into hospital workflows to assist clinicians in monitoring treatment response, disease progression, and recurrence,” said Dr. Ethan Shen, Chairman and CEO of YD Bio Limited.
YD Bio notes that early use at these centers may demonstrate clinical and economic value, which could support wider adoption across additional institutions. Broader uptake, if achieved, may contribute to diagnostics revenue growth and inform future therapeutic development.